Edition:
United States

Agile Therapeutics Inc (AGRX.OQ)

AGRX.OQ on NASDAQ Stock Exchange Global Market

3.45USD
26 May 2017
Change (% chg)

$-0.01 (-0.29%)
Prev Close
$3.46
Open
$3.45
Day's High
$3.46
Day's Low
$3.37
Volume
12,002
Avg. Vol
51,368
52-wk High
$8.65
52-wk Low
$1.82

Latest Key Developments (Source: Significant Developments)

Agile Therapeutics board appointed CEO Al Altomari as chairman of board
Thursday, 6 Oct 2016 05:53pm EDT 

Agile Therapeutics Inc : On October 5, 2016, board appointed Al Altomari, president and CEO, as chairman of board effective immediately - SEC filing Source: (http://bit.ly/2dOmS1B) Further company coverage: [AGRX.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Agile Therapeutics enters into first amendment to loan, security agreement with Hercules Capital, other banks, other financial institutions
Friday, 26 Aug 2016 04:43pm EDT 

Agile Therapeutics Inc : Entered into first amendment to loan and security agreement with Hercules Capital, Inc, other banks,other financial institutions . First amendment extends interest-only payments until January 31, 2017 in connection with first tranche of $16.5 million of term loan .Amendment extends co's option to draw down second tranche of $8.5 million of term loan facility provided under loan agreement until Mar 31,2017.  Full Article

Agile Therapeutics reports Q2 loss per share $0.29
Monday, 8 Aug 2016 04:05pm EDT 

Agile Therapeutics Inc : Agile Therapeutics reports second quarter 2016 financial results . Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.29 . Says as of june 30, 2016 $59.2 million of cash and cash equivalents compared to $34.4 million as of december 31, 2015 .Says cash and cash equivalents will be sufficient to meet its operating requirements through end of 2017.  Full Article

Agile Therapeutics reports Q1 loss per share $0.27
Monday, 9 May 2016 04:10pm EDT 

Agile Therapeutics Inc : Cash expected to fund operations through end of 2017 . Agile therapeutics reports first quarter 2016 financial results . Q1 loss per share $0.27 .Q1 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.  Full Article

Agile Therapeutics Inc announces proposed offering of common stock
Thursday, 21 Jan 2016 04:06pm EST 

Agile Therapeutics Inc:Intends to offer and sell $30 million of shares of its common stock.  Full Article

Agile Therapeutics Inc announces issuance of patent for Twirl Patch Design
Friday, 12 Jun 2015 07:40am EDT 

Agile Therapeutics Inc:Says the U.S. Patent and Trademark Office issued US Patent 9,050,358 on June 9.Newly-issued patent includes claims directed to peripheral adhesive system used in the Company's lead product candidate Twirla (ethinyl estradiol and levonorgestrel transdermal system (AG200-15)), currently in Phase 3 development.Patent includes claims that relate to enhanced adhesion characteristics of Twirla patch combined with its low rates of skin irritation.  Full Article

More From Around the Web